Compare IPCA Labs with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs AUROBINDO PHARMA - Comparison Results

IPCA LABS     Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS AUROBINDO PHARMA IPCA LABS/
AUROBINDO PHARMA
 
P/E (TTM) x 22.4 9.9 227.3% View Chart
P/BV x 4.3 1.8 235.6% View Chart
Dividend Yield % 0.3 0.6 48.9%  

Financials

 IPCA LABS   AUROBINDO PHARMA
EQUITY SHARE DATA
    IPCA LABS
Mar-19
AUROBINDO PHARMA
Mar-19
IPCA LABS/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs1,042830 125.5%   
Low Rs590527 112.0%   
Sales per share (Unadj.) Rs298.6333.9 89.4%  
Earnings per share (Unadj.) Rs35.040.4 86.7%  
Cash flow per share (Unadj.) Rs49.451.8 95.5%  
Dividends per share (Unadj.) Rs3.002.50 120.0%  
Dividend yield (eoy) %0.40.4 99.8%  
Book value per share (Unadj.) Rs247.1237.1 104.2%  
Shares outstanding (eoy) m126.35585.91 21.6%   
Bonus/Rights/Conversions ESOSESOP-  
Price / Sales ratio x2.72.0 134.5%   
Avg P/E ratio x23.316.8 138.7%  
P/CF ratio (eoy) x16.513.1 125.9%  
Price / Book Value ratio x3.32.9 115.4%  
Dividend payout %8.66.2 138.4%   
Avg Mkt Cap Rs m103,108397,569 25.9%   
No. of employees `00013.417.9 75.3%   
Total wages/salary Rs m7,87425,849 30.5%   
Avg. sales/employee Rs Th2,807.010,956.9 25.6%   
Avg. wages/employee Rs Th585.81,447.7 40.5%   
Avg. net profit/employee Rs Th329.01,324.3 24.8%   
INCOME DATA
Net Sales Rs m37,732195,636 19.3%  
Other income Rs m5771,553 37.1%   
Total revenues Rs m38,309197,189 19.4%   
Gross profit Rs m6,90139,519 17.5%  
Depreciation Rs m1,8246,680 27.3%   
Interest Rs m1892,626 7.2%   
Profit before tax Rs m5,46531,767 17.2%   
Minority Interest Rs m027 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-881 0.0%   
Tax Rs m1,0427,269 14.3%   
Profit after tax Rs m4,42223,645 18.7%  
Gross profit margin %18.320.2 90.5%  
Effective tax rate %19.122.9 83.4%   
Net profit margin %11.712.1 97.0%  
BALANCE SHEET DATA
Current assets Rs m23,778153,645 15.5%   
Current liabilities Rs m10,975120,429 9.1%   
Net working cap to sales %33.917.0 199.8%  
Current ratio x2.21.3 169.8%  
Inventory Days Days104135 76.7%  
Debtors Days Days6664 103.5%  
Net fixed assets Rs m20,368103,909 19.6%   
Share capital Rs m253586 43.1%   
"Free" reserves Rs m30,971138,322 22.4%   
Net worth Rs m31,224138,908 22.5%   
Long term debt Rs m1,4091,800 78.3%   
Total assets Rs m45,507264,544 17.2%  
Interest coverage x30.013.1 228.7%   
Debt to equity ratio x00 348.2%  
Sales to assets ratio x0.80.7 112.1%   
Return on assets %10.19.9 102.0%  
Return on equity %14.217.0 83.2%  
Return on capital %17.323.8 72.7%  
Exports to sales %45.90-   
Imports to sales %16.60-   
Exports (fob) Rs m17,308NA-   
Imports (cif) Rs m6,266NA-   
Fx inflow Rs m17,30897,316 17.8%   
Fx outflow Rs m6,26640,589 15.4%   
Net fx Rs m11,04256,727 19.5%   
CASH FLOW
From Operations Rs m4,92316,220 30.3%  
From Investments Rs m-1,563-28,768 5.4%  
From Financial Activity Rs m-1,83219,191 -9.5%  
Net Cashflow Rs m1,5286,656 23.0%  

Share Holding

Indian Promoters % 45.9 54.1 84.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.4 8.0 143.4%  
FIIs % 25.3 27.7 91.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 10.2 170.6%  
Shareholders   36,892 69,601 53.0%  
Pledged promoter(s) holding % 2.1 8.6 25.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   PIRAMAL ENTERPRISES  GSK PHARMA  DR. DATSONS LABS  DR. REDDYS LAB  NOVARTIS  

Compare IPCA LABS With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 248 Points Lower; Power and IT Stocks Witness Selling(Closing)

Indian share markets fell sharply during closing hours today and ended deep in the red. The BSE Sensex stood lower by 248 points, while the NSE Nifty closed down by 81 points.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 4.6% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 4.6% YoY). Sales on the other hand came in at Rs 56 bn (up 17.9% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

IPCA LABS Announces Quarterly Results (2QFY20); Net Profit Up 63.7% (Quarterly Result Update)

Nov 12, 2019 | Updated on Nov 12, 2019

For the quarter ended September 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 63.7% YoY). Sales on the other hand came in at Rs 12 bn (up 21.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

AUROBINDO PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Nov 6, 2019 | Updated on Nov 6, 2019

Here's an analysis of the annual report of AUROBINDO PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

IPCA LABS Announces Quarterly Results (1QFY20); Net Profit Up 101.5% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 101.5% YoY). Sales on the other hand came in at Rs 10 bn (up 18.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 38.6% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 38.6% YoY). Sales on the other hand came in at Rs 54 bn (up 28.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

More Views on News

Most Popular

Could this Smallcap Be the Next Page Industries?(Profit Hunter)

Nov 27, 2019

A single stock - Coca Cola, made Buffett billions. Here's your chance to break into the crorepati club with a single smallcap stock investment.

A Simple, 7-Step Checklist for Your Trading Success

Dec 4, 2019

What we can learn from one of the greatest traders to have ever lived.

Growth Stocks or Value Stocks... What Will Make You More Money in this Bull Market?(Profit Hunter)

Nov 28, 2019

Should you invest in growth stocks or value stocks to make strong returns in this market?

The Best Trading Strategy for Fast Profits

Nov 29, 2019

Vijay and I have decided to team up and bring you a unique offering never seen before in the Indian stock markets.

This PSU Turned into a Rare 100 Bagger. Others May Follow.(The 5 Minute Wrapup)

Nov 27, 2019

The lowest hanging fruit for government to raise capital would be to sell off stakes in non-critical PSUs.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Dec 10, 2019 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IPCA LABS 8-QTR ANALYSIS

COMPARE IPCA LABS WITH

MARKET STATS